Table II.
Haematopoietic recovery, graft-versus-host disease and survival outcomes
| Outcomes | Evaluated (n) | Probability (95% CI) |
|---|---|---|
| Neutrophil recovery >0.5 × 109/l | 478 | |
| 28-day | 94 (92–96)% | |
| 100-day | 96 (94–98)% | |
| Platelet recovery ≥ 20 × 109/l | 374 | |
| 28-day | 83 (78–86)% | |
| 100-day | 89 (86–92)% | |
| Acute GVHD (II-IV)* | 151 | |
| 100-day | 36 (28–44)% | |
| Acute GVHD (III-IV)* | 151 | |
| 100-day | 15 (10–21)% | |
| Chronic GVHD | 454 | |
| 6 month | 26 (22–30)% | |
| 1-year | 40 (35–44)% | |
| 3-year | 47 (42–51)% | |
| Extensive chronic GVHD | 454 | |
| 1-year | 33 (28–37)% | |
| NRM | 494 | |
| 1-year | 23 (19–27)% | |
| 3-year | 30 (26–34)% | |
| 5-year | 31 (27–36)% | |
| Relapse/Progression | 494 | |
| 1-year | 33 (29–37)% | |
| 3-year | 38 (34–43)% | |
| 5-year | 40 (36–45)% | |
| Progression-free Survival | 494 | |
| 1-year | 44 (40–48)% | |
| 3-year | 31 (27–36)% | |
| 5-year | 29 (24–33)% | |
| Overall survival | 503 | |
| 1-year | 54 (49–58)% | |
| 3-year | 37 (32–41)% | |
| 5-year | 34 (30–39)% |
*
Applies to patients with CRF-level data
GVHD = graft-versus-host disease; NRM = non-relapse mortality; CI = confidence interval.